Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone

Inclusion Criteria: * Male/female, age 18-78 inclusive * Type 2 diabetes, taking glargine, metformin and/or thiazolidinedione for 3 months prior to screening, stable doses for 2 months prior to screening * HbA1c 7.0-8.5% inclusive * Fasting plasma glucose \<240 mg/dL at screening * Body Mass Index 22-41 kg/m2 Exclusion Criteria: * Pregnant or nursing * Other investigational drugs within 30 days of screening * Treatment with other anti-diabetic medications other than metformin, glargine and/or thiazolidinedione * History of type 1 diabetes * Abnormal kidney function * History of acute diabetic complications * Congestive heart failure requiring treatment * Myocardial infarction, coronary artery surgery, stroke within 6 months of screening * Liver disease, liver enzymes more than 3 times upper limit of normal * Fasting triglycerides \>700 mg/dL within past 12 weeks * Acute infections or other conditions that may affect blood sugar or may interfere with interpretation of study data * Treatment with corticosteroids * Blood donation within past 12 weeks Other protocol-defined inclusion/exclusion criterial may apply.